logo
  

Rockwell Automation Cuts FY22 Earnings View Below Market Estimates - Update

While reporting sharply lower second-quarter earnings and higher sales on Tuesday, Rockwell Automation, Inc. (ROK) trimmed its forecast for fiscal 2022 earnings and sales growth view.

In pre-market activity on the NYSE, Rockwell Automation shares were losing around 8.4 percent to trade at $229.

The company said the guidance reflects its strong demand and record backlog along with its latest view of supply chain constraints. However, the global supply chain remains volatile with new pressures from COVID-19 related shutdowns in China and war in Ukraine that are difficult to quantify.

For the year, the company now expects earnings per share between $7.60 and $8.20, lower than previous estimate of $10.01 to $10.61. Adjusted earnings per share are now expected to be in the range of $9.20 - $9.80, down from earlier expected $10.50 - $11.10.

On average, 26 analysts polled by Thomson Reuters expect earnings of $10.66 per share for the year. Analysts' estimates typically exclude special items.

Further, the company now expects reported sales growth of 11 percent to 15 percent, down from previous growth view of 16 percent to 19 percent. Organic sales growth is now expected to be 10 percent to 14 percent, compared to previously expected sales growth of 14 percent to 17 percent.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Longmont Colorado -based Royal Crest Dairy is recalling 2% Chocolate Milk citing the potential to be contaminated with undeclared egg, a known allergen, the U.S. Food and Drug Administration said. The recall involves Farmer's 2% Reduced Fat Chocolate Milk Pints with the code date of AUG-22. ANI Pharmaceuticals, Inc. (ANIP) Monday announced a wider loss for the second quarter, despite a 52 percent surge in revenues. For the full year 2022, the company reiterated the adjusted earnings per share range, revenue guidance and raised Cortrophin revenue outlook. The company reported a quarterly... Shares of BioNTech SE were losing around 4 percent in the morning trading in Germany and around 5 percent in the pre-market activity on Nasdaq after the German Covid-19 vaccine maker reported sharp drop in profit and revenues for the second quarter. However, the company recorded strong growth in first-half results. Further, the company maintained BioNTech COVID-19 vaccine revenue guidance
Follow RTT